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Abstract 
Background: Hypertension is considered the most serious risk factor for cardiovascular disease. Angiotensin-con-
verting enzyme inhibitory peptides (ACEIPs), which are made from tuna frame protein (TFP) and yellow fin sole frame 
protein (YFP), have been used previously to treat hypertension. However, the production of these short peptides is 
usually dependent on enzymatic hydrolysis, resulting in a digested mixture that makes it difficult to purify the ACEIPs. 
Although it has been reported that ACEIPs could be produced in recombinant Escherichia coli strains, the use of lactic 
acid bacteria in the production of ACEIPs has not been demonstrated.
Results: In this study, the ACEIP coding sequences from TFP and YFP were joined through an arginine linker and 
expressed in the Lactobacillus plantarum (Lb. plantarum) NC8 strain by an inducible vector pSIP-409. Then, the antihy-
pertensive effects were determined in the model of spontaneously hypertensive rats (SHRs) by measuring the blood 
pressure, hematology, blood biochemistry and nitric oxide (NO), endothelin (ET) and angiotensin II (Ang II) levels. The 
results showed that oral administration of recombinant Lb. plantarum NC8 (RLP) significantly decreased systolic blood 
pressure (P < 0.01) during treatment, which lasted for at least 10 days after the last dose. Furthermore, the presence 
of RLP resulted in an increased level of NO, as well as decreased levels of ET and Ang II in plasma, heart, and kidney. In 
addition, a dramatically decreased triglyceride level was also observed even though there was no significant change 
in hematology or blood biochemistry. Although some drawbacks were still observed, such as the presence of an 
antibiotic selection marker, no obvious side effects or bacterial translocation were observed in vivo, indicating the 
potential application of RLP in the treatment of hypertension.
Conclusion: These results demonstrated the effectiveness and safety of RLP on the treatment of hypertension.
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Background
Approximately twenty percent of the world’s population 
is susceptible to serious hypertension (HTN), which is 
a frequent cause of cardiovascular diseases, the leading 
cause of death globally [1]. As a frequent and chronic 
age-related disorder, it has been demonstrated that HTN 
is usually accompanied with other cardiovascular risk 
factors, including abdominal obesity, dyslipidemia, glu-
cose intolerance, hyperinsulinemia, and hyperuricemia 
[2]. According to previous reports, the kidneys play a 
central part in the pathophysiology of essential hyperten-
sion; therefore, kidney disorders, such as renal ischemia 
[3], have been considered the most critical risk factor 
for HTN. In addition, obstructive sleep apnea has been 
newly recognized as a secondary cause of HTN accord-
ing to the Seventh Joint National Committee [4]. Other 
factors such as hypothyroidism [5] and nitric oxide 
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deficiency [6] have also been identified as risk factors for 
HTN.
The renin-angiotensin system (RAS) plays an impor-
tant role in maintaining blood pressure homeostasis in 
addition to the fluid and salt balance in mammals [7]. 
Angiotensin-converting enzyme (ACE) is a dipeptidyl 
carboxypeptidase that plays an important physiological 
role in regulating blood pressure by virtue of the RAS [8]. 
In the RAS, ACE converts inactive peptide angiotensin I 
(Ang I) into powerful vasoconstrictor angiotensin II (Ang 
II) and inactivates the catalytic function of bradykinin 
[9–11].
Since the discovery of ACE inhibitors in snake venom 
[12], many synthetic inhibitors have been developed and 
are currently used in the treatment of essential hyperten-
sion and heart failure in humans; these inhibitors include 
captopril [13], enalapril [14], alacepril [15] and lisino-
pril [16]. However, these synthetic ACE inhibitors are 
believed to have certain negative effects such as cough, 
taste disturbances, skin rashes and other serious diseases 
[17]. Recently, a series of natural ACE inhibitory peptides 
(ACEIPs) have been produced either by protein hydroly-
sis [18] or recombinant technologies [19, 20] without any 
obvious side effects, indicating their great application 
potential. One of these ACEIPs belongs to the family of 
the yellowfin sole (Limanda aspera) frame protein (YFP), 
with a molecular mass of 1.3  kDa and 11 amino acids. 
After peptide ingestion, blood pressure significantly 
decreased in spontaneously hypertensive rats (SHRs) 
[21]. Similar beneficial effects were also observed dur-
ing a study in which a 21-amino-acid peptide from tuna 
frame protein (TFP) dramatically decreased blood pres-
sure in the SHR model [22].
Lactic acid bacteria (LAB) include a group of Gram-
positive, nonsporulating cocci and rod-shaped anaerobic 
bacteria, producing lactic acid as the major metabolite of 
carbohydrate fermentation. LAB have been used widely 
in the production of fermented foods for centuries, and 
several LAB have been recognized as probiotics because 
of their wide health-promoting effects in humans. The 
most widely documented effects of LAB include improved 
immune function [23], prevention and reduced intensity 
of diarrhea [24], and reduced lactose intolerance [25]. 
One of the LAB that has been studied in the most detail is 
Lactobacillus plantarum (Lb. plantarum). In addition to 
its natural beneficial properties, Lb. plantarum has been 
genetically engineered to express protective antigens [26, 
27], β-galactosidase [28], or oxalate decarboxylase [29] for 
medical applications. Most recently, the engineered Lb. 
plantarum has also been considered an alternative strat-
egy for delivering DNA vaccines [30].
In the present study, we investigated the production of 
recombinant ACEIPs from both YFP and TFP in the Lb. 
plantarum NC8 strain and evaluated the biological and 
safety effects. The results show that oral administration 
of RLP dramatically decreases blood pressure, endothelin 
(ET) and Ang II production, and triglyceride levels with 
no observed side effects, indicating its potential applica-
tion in hypertension and related diseases.
Results
Construction of recombinant pSIP409‑ACEIP vector 
and expression of recombinant ACEIP in Lb. plantarum NC8
The encoding sequences of peptides from YFP and TFP 
were synthesized and joined through an arginine linker 
as shown in Fig. 1a. After digestion by NcoI and HindIII, 
the gusA gene present in pSIP409 was replaced with 
genes encoding an ACEIP fusion protein, which was 
confirmed by restriction endonuclease digestion and 
sequencing (data not shown), yielding the recombinant 
expression vector pSIP409-ACEIP (Fig.  1b). The SDS-
PAGE and western blotting results showed that a specific 
protein band of approximately 8.5 kDa was expressed in 
Lb. plantarum NC8 (Fig. 2).
Antihypertensive activity of recombinant Lb. plantarum 
NC8 (RLP)
Antihypertensive activity of RLP was evaluated by meas-
uring the systolic blood pressure (SBP) every day during 
the first 15 days and then on day 19 and day 24 (Fig. 3). 
The results showed that the SBP in the RLP-treated group 
decreased dramatically as time elapsed, with the lowest 
value of 167.111 ±  3.418  mmHg occurring on the 15th 
day, which was significantly lower (P  <  0.01) than the 
184.810 ± 4.305 mmHg in the Lb. plantarum group and 
the 197.443 ± 3.893 mmHg in the PBS group. Although 
the SBP values in the RLP group increased after the last 
dose at day 15, the antihypertensive function of RLP 
was maintained for at least 10  days because the SBP of 
the RLP-treated rats (181.517 ±  2.312  mmHg) was sig-
nificantly lower than that of the Lb. plantarum treated 
rats (195.876 ±  2.109  mmHg) and the PBS control rats 
(197.376  ±  4.982  mmHg) on the 24th day (P  <  0.05). 
Interestingly, the PBS control rats maintained hyper-
tensive status during the entire study. In addition, we 
observed that the administration of Lb. plantarum also 
decreased the SBP level in rats compared with the PBS 
controls, with lowest values of approximately 185 mmHg 
on day 15. All the results mentioned above clearly dem-
onstrated that the administration of RLP in rats signifi-
cantly decreased the SBP level because of the presence of 
recombinant ACEIP.
Hematology and blood biochemistry
The hematological parameters and blood biochemical 
indices in each group were also determined (Table  1). 
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The values of hematocrit (HCT), total plasma choles-
terol (TCHE) and triglyceride (TG) were significantly 
decreased in the RLP-treated rats compared with the PBS 
controls, whereas the levels of TCHE and TG in the RLP-
treated rats were even lower than in the rats treated with 
NC8 alone (P < 0.05).
Effects of RLP on nitric oxide (NO), ET and Ang II levels 
in plasma, kidney and heart
The NO values in plasma, kidneys and hearts of the RLP-
treated rats increased significantly compared with those 
in the PBS control rats (P < 0.001) (Fig. 4a). By contrast, 
the Ang II (Fig. 4b) and ET (Fig. 4c) values in plasma, kid-
neys and hearts of the RLP-treated rats decreased dra-
matically compared with those of the PBS controls. In 
addition, we also noticed that the presence of NC8 alone 
also increased the levels of NO and decreased the levels 
of AngII and ET compared to the PBS controls (Fig. 4).
Safety evaluation of RLP in mice
To determine the safety of RLP, an acute toxicity test 
(ATT), a bone marrow cell micronucleus test (BMCMT) 
and a bacterial dissemination test (BDT) were per-
formed. The results of ATT did not show any potential 
Fig. 1 Construction of recombinant plasmid pSIP409-ACEIP. a Designed peptide sequences according to the synthesized oligonucleotides. Black 
bold, peptides of tuna frame protein; Black bold italic, arginine linker; Underlined, peptides of limanda aspera frame protein; Black bold underlined, 
His tag. b Illustration of pSIP409-ACEIP. Encoding sequences of angiotensin-converting enzyme inhibitory peptide (ACEIP) were digested by NcoI 
and HindIII and were ligated with pSIP409 that was digested with the same enzymes. 256rep replication origin for Lactobacillus, ermL erythromycin-
resistance marker, PsppIP and PorfX inducible promoters, sppK and sppR histidine protein kinase and response regulator, respectively
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adverse effect on general health status, body weight gain, 
morphology (data not shown) or weight of spleen and 
liver (Table  2). The results of the BMCMT test demon-
strated that the micronucleus ratio in RLP-treated mice 
(2.7 ‰) was almost the same as that of the negative PBS 
control (2.5 ‰), whereas the ratio in cyclophosphamide 
(CP)-injected mice was significantly higher (27.3 ‰). In 
addition, no viable bacteria were recovered from blood, 
spleen or liver in any groups according to the results 
of the BDT (data not shown), indicating that repeated 
administration of a high dose of RLP did not induce bac-
teria translocation. Consistent with a previous study, 
body weight gain was still not affected by RLP treat-
ment (data not shown). All the results mentioned above 
demonstrated that oral administration of RLP was safe, 
at least in experimental conditions. However, there was 
still an obvious limitation in our system: the presence of 
an antibiotic selection marker (Erm+) would prevent us 
from using this system in a clinical trial. Thus, further 
studies to exchange the Erm-resistant gene with a food-
grade selection marker would be necessary.
Discussion
Oral administration of ACEIPs has been demonstrated 
to be effective in the control of HBP in SHR models 
even though the antihypertensive effect could last for 
only a few hours after treatment cessation [31–33]. One 
of the possible explanations for the short-lasting effects 
was that the administered ACEIP could be digested rap-
idly in  vivo because of the direct exposure to the host’s 
Fig. 2 Protein profiles of Lb. plantarum NC8 on SDS-PAGE. Lb. 
plantarum NC8 harboring pSIP409-ACEIP was induced with 50 ng/
mL of sakasin-P (SppIP)-inducing peptide at OD600 = 0.6 and then 
the induced cells were harvested at 7 h by centrifugation and were 
suspended in 50 mM phosphate buffer, followed by sonic disrup-
tion. The cell-free extract was analyzed on 17.5 % sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and subjected 
to western blotting (WB) using rabbit anti-His polyclonal antibody 
as prime antibody. Lane 1 protein marker; lane 2 non-induced Lb. 
plantarum NC8 (SDS-PAGE); lane 3 induced Lb. plantarum NC8 at 
7 h (SDS-PAGE); lane 4 non-induced Lb. plantarum NC8 (WB); lane 5 
induced Lb. plantarum NC8 at 7 h (WB)
Fig. 3 Change of systolic blood pressure (SBP) after oral administra-
tion of recombinant Lb. plantarum NC8 (RLP) strain in spontaneously 
hypertensive rat. The rats were treated orally with either RLP or Lb. 
plantarum NC8 (NC8) at a dose of 2 × 1011 CFU for 14 continuous 
days, whereas additional PBS-treated rats were included as controls. 
The SBP was continuously determined during the first 15 days and 
then at day 19 and day 24 as described in the methods section. 
The statistical significance was calculated by one-way ANOVA test. 
*P < 0.05; **P < 0.01 vs. PBS control
Table 1 Haematology and  blood biochemistry measure-
ments (mean ±  SEM) of  spontaneously hypertensive rats 
(SHR)
The rats were divided into three groups and subjected to either PBS, L. planturm 
NC8 (NC8) or recombinant Lb.Plantarum NC8 (RLP) treatment for continuous 
14 days, and then 5 rats from each group were selected at random at day 14 
and the cardiac puncture samples were collected and the following values were 
measured
WBC white blood cell, RBC red blood cell, HGB haemoglobin, HCT hematocrit, 
MCV mean corpuscular volume, MCH mean corpuscular haemoglobin, MCHC 
mean corpuscular haemoglobin concentration, PLT platelet counts, W-SCR 
lymphocyte percentage, W-SCC absolute value of lymphocyte, PDW platelet 
distribution width, MPV mean platelet volume, P-LCR platelet large cell ratio, 
UREA urea nitrogen, GLUC total plasma glucose, TCHE total plasma cholesterol, 
TG triglyceride
The statistical significance was calculated using one way ANOVA.* P < 0.05 vs. 
PBS control. # P < 0.05 vs. NC8 control
Parameters PBS NC8 RLP
WBC (109/L) 5.133 ± 1.935 5.567 ± 0.929 5.400 ± 2.272
RBC (1012/L) 6.810 ± 0.764 6.727 ± 0.748 7.620 ± 0.735
HGB (g/L) 94.33 ± 14.154 102.33 ± 6.658 113.00 ± 10.583
HCT (%) 0.308 ± 0.013 0.320 ± 0.047 0.382 ± 0.034*
MCV (fL) 50.500 ± 0.700 50.000 ± 1.200 50.133 ± 0.351
MCH (pg) 14.133 ± 0.902 15.667 ± 0.757 14.833 ± 0.058
MCHC (g/L) 296.00 ± 30.610 314.00 ± 22.113 295.67 ± 1.155
PLT (109/L) 533.33 ± 59.181 589.33 ± 36.611 661.67 ± 289.096
W-SCR (%) 0.752 ± 0.064 0.607 ± 0.132 0.793 ± 0.159
W-SCC (%) 3.000 ± 0.600 3.133 ± 0.231 4.400 ± 2.193
RDW-SD (fL) 29.000 ± 0.100 29.033 ± 0.379 28.800 ± 0.625
RDW-CV (%) 0.147 ± 0.001 3.147 ± 5.198 0.148 ± 0.009
PDW (fL) 7.500 ± 0.100 7.733 ± 0.451 7.967 ± 0.643
MPV (fL) 6.200 ± 0.100 6.433 ± 0.231 6.700 ± 0.361
P-LCR (%) 0.030 ± 0.011 0.042 ± 0.009 0.047 ± 0.013
UREA (mmol/L) 8.343 ± 1.517 8.340 ± 0.963 7.700 ± 1.908
GLUC (mmol/L) 16.570 ± 2.370 14.300 ± 2.383 15.480 ± 1.019
TCHE (mmol/L) 1.360 ± 0.044 1.333 ± 0.125 1.100 ± 0.050*,#
TG (mmol/L) 1.247 ± 0.025 1.213 ± 0.176 0.750 ± 0.181*,#
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internal environment. Accordingly, it was reasonable to 
deduce that the ACEIP delivered by a bacteria host would 
perform better during the treatment of HBP because of 
the protective effects provided by the host strains. Our 
results demonstrated that the antihypertensive effect 
of RLP-expressing ACEIP lasted at least an additional 
10 days after the last administered dose.
In fact, the administration of Lb. plantarum alone also 
decreased the BP levels during at least the first 15 days, 
with the lowest value at day 9 (Fig. 3). It has previously 
been reported that the administration of probiotic-fer-
mented products had some beneficial effects in reducing 
blood pressure in patients with hypertension [34–36], by 
releasing bioactive peptides such as ACEIP during the 
fermentation process [37]. Another possible explanation 
of the observed effect involve the maintenance of the gut 
microbiota balance, which has gained increasing atten-
tion recently in the field of human health. The imbalance 
of gut microbiota has been primarily associated with gas-
trointestinal health disorders and other diseases such as 
Parkinson’s disease [38], fatty liver disease [39], diabetes 
[40] and hypertension [41]. Therefore, the administra-
tion of probiotics could possibly restore the microbiota 
Fig. 4 Effects of recombinant Lb. plantarum NC8 (RLP) on the levels of nitric oxide (NO) (a), angiotensin II (Ang II) (b) and endothelin (ET) (c) in the 
plasma, kidneys and hearts of spontaneously hypertensive rats. The rats were orally treated with either RLP, Lb. plantarum NC8 or PBS for 14 continu-
ous days, and then the samples were collected from 5 rats in each group at day 14. The measurements of NO, ET and Ang II levels were performed 
using ELISA kits, and the statistical significance was calculated by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001 vs. PBS control
Table 2 The change of spleen, liver and body weight ratio
The liver and body weight ratio (LW/BW), spleen and body weight ratio (SW/BW) 
were calculated in two separate studies, including the acute toxicity test (ATT, 
labeled as “a”) and bacterial dissemination test (BDT, labeled as “b”). There were 
three groups in both studies, PBS control, low dose (4.5 × 107  CFU) and high 
dose (4.5 × 109 CFU) treatment. The mice in ATT study were orally administrated 
for 3 days and observed for additional 7 days, whereas the mice in BDT assay 
were treated for 4 weeks
Groups LW/BW SW/BW
PBSa 0.050 ± 0.0082 0.0045 ± 0.0016
4.5 × 107CFUa 0.055 ± 0.0058 0.0047 ± 0.0013
4.5 × 109CFUa 0.046 ± 0.0079 0.0042 ± 0.0017
PBSb 0.054 ± 0.0057 0.0059 ± 0.0014
4.5 × 107CFUb 0.065 ± 0.0063 0.0052 ± 0.0018
4.5 × 109CFUb 0.045 ± 0.0061 0.0051 ± 0.0017
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balance, thus improving endothelial dysfunction, vascu-
lar inflammation, vascular oxidative stress, cardiac and 
renal hypertrophy to reduce high BP in the SHR model 
[37].
In the present study, the mechanism of RLP in lower-
ing blood pressure was further identified. The ET and 
Ang II levels in plasma, kidneys and hearts of the RLP-
treated SHRs dramatically decreased compared with 
that of the rats treated with Lb. plantarum NC8 or PBS. 
However, the NO values in the RLP-treated SHR group 
increased significantly compared with that of the two 
control groups. NO is mainly produced by vascular 
endothelial cells and is considered a strong vasodilat-
ing factor [42]. The presence of other types of ACEIPs 
has been demonstrated to be effective in reducing the 
NO level in serum and kidneys [43, 44]. In our case, RLP 
expressing the ACEIP fusion protein may promote the 
activity of NO synthesis and increase the release of NO, 
which could be responsible for the observed lower SBP 
in rats. Currently, it is believed that ET belongs to a fam-
ily of vasoconstrictive peptides and is distributed in the 
cardiovascular system. Previous studies have identified 
that Ang II could stimulate endothelial cells to produce 
ET [45]. In this study, the presence of RLP repressed the 
expression of Ang II and then resulted in the observed 
lower ET compared with that of the control rats, which 
could be responsible for the decreased SBP in the SHRs. 
However, the detailed mechanism is still not clear; there-
fore, further investigation will be necessary. In addition, 
this study also demonstrated that the oral administration 
of RLP could dramatically decrease blood TCHE and TG 
levels, consistent with the findings of previous reports 
with regard to the effects of ACEIP [43, 44]. The safety 
of RLP was also examined because probiotics should be 
innocuous whenever they are used; no obvious adverse 
effects or bacterial translocation were observed.
However, improvements to our system could be made 
as a result of this study. The first option is to explore a 
food-grade non-antibiotic selective marker, such as ala-
nine racemases [46], to exchange the erythromycin-
resistance gene. Another reasonable approach is to make 
use of surface anchoring [47] or secreting methods [48] 
to enhance the interaction of ACEIPs with the host envi-
ronment, which have been shown to be better in induc-
ing an immune response than the intracellular expression 
system that was used in our study.
Conclusions
In this study, we constructed an effective RLP strain that 
expressed two sources of ACEIP by protein fusion. The 
oral administration of RLP significantly decreased the 
SBP, TG, ET and Ang II levels in the SHR model and 
increased the NO level. Most importantly, this is the first 
report showing that ACEIPs could be produced in LAB; 
oral administration of RLP leads to the longest decreased 
effects on SBP currently found in the literature.
Methods
Bacterial strains, plasmids and animals
The bacterial strains and plasmids used in this study 
are listed in Table  3. E. coli DH5α cells were grown in 
Luria–Bertani medium at 37  °C with shaking, and Lb. 
plantarum NC8 cells [49] were grown aerobically in 
MRS medium at 30 °C without shaking. Solid media were 
prepared by adding 1.5 % (w/v) agar to the broth. When 
required, erythromycin was added as follows: 200 μg/mL 
for E. coli and 50 μg/mL for Lb. plantarum. The E. coli-
Lactobacillus shuttle vector pSIP409 [49] was used as the 
expression vector through the entire study. SHRs with a 
tail SBP greater than 180 mmHg and BALB/c mice were 
obtained from Beijing Vital River Laboratory Animal 
Technology Co. Ltd. (Beijing, China). SHRs were housed 
individually in steel cages in a room kept at 24 °C with a 
12 h light–dark cycle and were fed a standard laboratory 
diet. Tap water was freely available.
Design of ACEIP oligonucleotides
The ACEIP oligonucleotides were designed based on 
previously published peptide sequence information [21, 
22]. In detail, the 21-mer peptide (Gly-Asp-Leu-Gly-
Lys-Thr-Thr–Thr-Val-Ser-Asn-Trp-Ser-Pro-Pro-Lys-
Try-Lys-Asp-Thr-Pro) from TFP and 11-mer peptide 
(Met-Ile-Phe-Pro-Gly-Ala-Gly–Gly-Pro-Glu-Leu) from 
YFP were connected by an arginine linker, followed by 
another duplicate repeat and a 6× His tag (Fig. 1a). The 
corresponding nucleotides were codon optimized to 
maximize the expression in both E. coli and Lb. plan-
tarum. The complementary oligonucleotides containing 
two restriction sites (NcoI and HindIII) were synthesized 
by BGI Beijing Corporation (Beijing, China), namely 
pUC57-ACEIP.
Construction of recombinant plasmid and transformation
The ACEIP-containing DNA fragment was released from 
pUC57-ACEIP by double digestion with NcoI and HindIII 
and was inserted into pSIP409 digested with the same 
enzymes, yielding pSIP409-ACEIP (Fig. 1b). E. coli DH5α 
was used as the recipient strain for the recombinant plas-
mids, and Lb. plantarum NC8 was selected as the expres-
sion host. Competent Lb. plantarum were transformed 
by electroporation as described previously [30] with 
some modifications. In detail, Lb. plantarum was grown 
overnight in MRS broth and then inoculated to an opti-
cal density of 0.3 at 600 nm in MRS with 2 % glycine and 
incubated at 30 °C. At an optical density of 0.6 at 600 nm, 
the cells were chilled on ice and harvested, washed twice 
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with ice-cold wash buffer and resuspended in 1/100 cul-
ture volume of electrode buffer. The competent cells were 
then subjected to a 2.5 kV, 5 ms electric pulse in a 0.2 cm 
cuvette, using a Gene Pulser (Bio-Rad, Richmond, CA, 
USA). Immediately after the pulse, cells were transferred 
to the 800 μL of MRS broth and were incubated at 30 °C 
for 2 h. The cells were plated on MRS agar containing the 
required antibiotic and were incubated for 24 h at 30 °C 
until visible colonies were observed.
Expression and identification of ACEIP protein in Lb. 
plantarum NC8
Lb. plantarum NC8 harboring pSIP409-ACEIP was 
induced with 50  ng/mL of sakasin-P (SppIP)-inducing 
peptide at OD600 =  0.6. A final concentration of 5  mM 
MnCl2 was added along with the peptide inducer. The 
induced cells were harvested at 7 h by centrifugation and 
were suspended in 50  mM phosphate buffer, followed 
by sonic disruption. The cell-free extract was analyzed 
on 17.5  % sodium dodecyl sulfate–polyacrylamide  gel 
electrophoresis (SDS-PAGE) and subjected to western 
blotting assay using rabbit anti-His polyclonal antibody 
(Sigma) as prime antibody.
Animal experiments
Twelve-week-old male SHRs (weight 200–260  g) were 
randomly divided into three groups, with 10 rats in each 
group. The rats in group I were orally treated with Lb. 
plantarum NC8 harboring pSIP409-ACEIP induced by 
50  ng/mL SppIP for 7  h at a dose of 2 ×  1011 CFU for 
14 continuous days; the rats in group II and III were 
exposed to either an equal dose of Lb. plantarum NC8 
or PBS, respectively, as negative controls. The SBP was 
continuously determined during the first 15  days and 
then at day 19 and day 24 using the tail-cuff method with 
a non-invasive blood pressure BP-98A measuring sys-
tem (Softron BP-98A, Tokyo, Japan) as described previ-
ously [50]. Five rats from each group were euthanized 
on the 14th day, and samples were collected for analysis 
of hematology, blood biochemistry, NO, ET and AngII 
levels.
Hematology and blood biochemistry analyses
Blood samples were obtained from a cardiac puncture 
using EDTA-treated tubes. Total red blood cell (RBC) 
and white blood cell (WBC), hemoglobin (HGB), hema-
tocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), platelet counts 
(PLT), lymphocyte percentage (W-SCR), absolute value 
of lymphocyte (W-SCC), red blood cell volume distribu-
tion width-standard deviation (RDW-SD), red blood cell 
volume distribution width-coefficient of variation (RDW-
CV), platelet distribution width (PDW), mean platelet 
volume (MPV) and platelet large cell ratio (P-LCR) were 
determined using a KX-21 N hematology Analyzer (Sys-
mex, Tokyo, Japan). Following completion of the hema-
tology assays, plasma was separated from blood samples. 
The levels of total plasma glucose (GLUC), urea nitrogen 
(UREA), total plasma cholesterol (TCHE) and triglycer-
ide (TG) were determined on a BS-400 Automatic bio-
chemical analyzer (Mindray, Shenzhen, China).
Measurement of NO, EU and AngII levels
The 2  mL blood samples that were mentioned above 
were collected and centrifuged at 1000×g for 15  min 
at 4  °C to collect the plasma. In addition, the heart and 
kidney samples were collected after homogenization by 
centrifugation at 1000×g for 20 min at 4 °C. Plasma and 
tissue homogenates were separated and stored at −70 °C 
until use. The concentrations of NO, ET and Ang II were 
determined by enzyme-linked immunosorbent assay 
(ELISA) kits (Rapidbio Inc, USA).
Safety evaluation of RLP
To evaluate the safety of RLP, ATT and BMCMT assess-
ments were performed as described previously with 
some modifications [51, 52]. Specifically, 6–8  week old 
BALB/c mice were divided randomly into three groups 
with 10 mice per group; the mice were subjected to either 
4.5  ×  109 CFU or 4.5  ×  107 CFU RLP resuspended in 
0.1 mL PBS. An additional 0.1 mL PBS served as the neg-
ative control. The animals were continuously treated for 
3 days and were observed for 7 days. Behavioral changes, 
including body weight, morbidity, mortality and clinical 
signs of toxicity, were recorded during experiments. On 
day 8, the mice were killed by decapitation under anes-
thesia, and the spleen and liver were collected to calculate 
Table 3 Bacterial strains and plasmids used in this study
Plasmids or strains Description Source
pUC57-ACEIP pUC57 with ACEIP;  
Ampr; 2.71 kb














E.coli DH5α Host strain TaKaRa Corporation, 
Japan
L. plantarum NC8 Host strain, Plasmid- 
free, silage isolate
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the ratio of spleen/liver to body weight and to perform 
histological analysis. Additionally, the other organs were 
also evaluated to determine the presence of any patho-
logical changes.
To perform the BMCMT assay, 30 BALB/c mice were 
randomly divided into three groups with 10 mice per 
group. The RLP group was orally treated with a dose 
of 4.5 × 108 CFU in 0.1 mL PBS for 5 continuous days, 
whereas the negative control group was treated with 
0.1 mL PBS for 5 days and the positive control group was 
intraperitoneally injected with CP 50 mg/kg (BW) on the 
5th day. Twenty-four hours after the last dose, the mice 
were sacrificed by cervical dislocation, and bone marrow 
cells were collected immediately as described before [52]. 
One thousand polychromatic erythrocytes (PCE) were 
recorded per mouse, and the frequency of micronucle-
ated cells was calculated by counting them and dividing 
by the total number of polychromatic erythrocytes.
Determination of RLP dissemination
The possibility of bacterial translocation in immunized 
mice was also evaluated as described previously with 
some modifications [53]. A total of 30 6–8  week old 
BALB/c mice were randomly divided into three groups 
with 10 mice per group. The mice were daily treated with 
either 4.5 × 107 CFU RLP (low dose) or 4.5 × 109 CFU 
RLP (high dose) that was resuspended in 0.1  mL PBS 
for 4 continuous weeks, whereas the administration of 
0.1  mL PBS was used as the negative control. Next, all 
the mice were sacrificed, and the spleen and liver of each 
individual mouse were aseptically removed, weighted 
and placed immediately into sterilized PBS at a ratio of 
1  mL/g. The samples were then mechanically homog-
enized and 0.1 mL samples were used on erythromycin-
selective MRS agar plates. The presence of antibiotic 
resistant colonies was then determined after a further 
48 h culture at 37 °C.
Statistical analysis
All data were expressed as the mean ±  SEM. Statistical 
analysis was performed using a two-tailed Student’s t test 
with GraphPad Prism 5.0 (GraphPad Software).
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